Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. more
Time Frame | CTSO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.58% | -2.06% | -0.55% |
1-Month Return | -7.74% | -1.92% | 2.72% |
3-Month Return | -39.58% | -10.4% | 7.66% |
6-Month Return | 13.94% | -4.6% | 10.15% |
1-Year Return | -53.11% | 4.06% | 27.53% |
3-Year Return | -79.86% | 1.94% | 32.31% |
5-Year Return | -78.44% | 36.48% | 89.2% |
10-Year Return | -88.08% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 22.77M | 39.45M | 40.11M | 29.36M | 36.35M | [{"date":"2019-12-31","value":56.76,"profit":true},{"date":"2020-12-31","value":98.36,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.2,"profit":true},{"date":"2023-12-31","value":90.63,"profit":true}] |
Cost of Revenue | 7.36M | 11.05M | 11.05M | 13.96M | 13.96M | [{"date":"2019-12-31","value":52.76,"profit":true},{"date":"2020-12-31","value":79.19,"profit":true},{"date":"2021-12-31","value":79.16,"profit":true},{"date":"2022-12-31","value":99.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 15.40M | 28.40M | 29.06M | 15.40M | 22.39M | [{"date":"2019-12-31","value":53,"profit":true},{"date":"2020-12-31","value":97.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.01,"profit":true},{"date":"2023-12-31","value":77.05,"profit":true}] |
Gross Margin | 67.65% | 71.98% | 72.46% | 52.47% | 61.60% | [{"date":"2019-12-31","value":93.37,"profit":true},{"date":"2020-12-31","value":99.35,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.41,"profit":true},{"date":"2023-12-31","value":85.02,"profit":true}] |
Operating Expenses | 34.38M | 38.77M | 51.81M | 46.93M | 53.60M | [{"date":"2019-12-31","value":64.13,"profit":true},{"date":"2020-12-31","value":72.33,"profit":true},{"date":"2021-12-31","value":96.65,"profit":true},{"date":"2022-12-31","value":87.55,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (18.97M) | (10.37M) | (22.75M) | (31.52M) | (31.21M) | [{"date":"2019-12-31","value":-1897400000,"profit":false},{"date":"2020-12-31","value":-1037000000,"profit":false},{"date":"2021-12-31","value":-2274500000,"profit":false},{"date":"2022-12-31","value":-3152200000,"profit":false},{"date":"2023-12-31","value":-3120925300,"profit":false}] |
Total Non-Operating Income/Expense | (2.42M) | 204.93K | (2.52M) | (2.25M) | 1.73M | [{"date":"2019-12-31","value":-139.73,"profit":false},{"date":"2020-12-31","value":11.84,"profit":true},{"date":"2021-12-31","value":-145.76,"profit":false},{"date":"2022-12-31","value":-130.08,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (20.36M) | (8.96M) | (25.30M) | (33.91M) | (29.32M) | [{"date":"2019-12-31","value":-2035800000,"profit":false},{"date":"2020-12-31","value":-896400000,"profit":false},{"date":"2021-12-31","value":-2529500000,"profit":false},{"date":"2022-12-31","value":-3390500000,"profit":false},{"date":"2023-12-31","value":-2932113300,"profit":false}] |
Income Taxes | (1.09M) | (1.13M) | (736.00K) | (1.09M) | (813.74K) | [{"date":"2019-12-31","value":-109200000,"profit":false},{"date":"2020-12-31","value":-112700000,"profit":false},{"date":"2021-12-31","value":-73600000,"profit":false},{"date":"2022-12-31","value":-109200000,"profit":false},{"date":"2023-12-31","value":-81373900,"profit":false}] |
Income After Taxes | (19.27M) | (7.84M) | (24.56M) | (32.81M) | (28.51M) | [{"date":"2019-12-31","value":-1926600000,"profit":false},{"date":"2020-12-31","value":-783700000,"profit":false},{"date":"2021-12-31","value":-2455900000,"profit":false},{"date":"2022-12-31","value":-3281300000,"profit":false},{"date":"2023-12-31","value":-2850739400,"profit":false}] |
Income From Continuous Operations | (19.27M) | (7.84M) | (24.56M) | (32.81M) | (28.51M) | [{"date":"2019-12-31","value":-1926564400,"profit":false},{"date":"2020-12-31","value":-783718800,"profit":false},{"date":"2021-12-31","value":-2455864800,"profit":false},{"date":"2022-12-31","value":-3281258300,"profit":false},{"date":"2023-12-31","value":-2850739400,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (19.27M) | (7.84M) | (24.56M) | (32.81M) | (28.51M) | [{"date":"2019-12-31","value":-1926600000,"profit":false},{"date":"2020-12-31","value":-783700000,"profit":false},{"date":"2021-12-31","value":-2455900000,"profit":false},{"date":"2022-12-31","value":-3281300000,"profit":false},{"date":"2023-12-31","value":-2850739400,"profit":false}] |
EPS (Diluted) | (0.59) | (0.21) | (0.57) | (0.76) | (0.65) | [{"date":"2019-12-31","value":-59,"profit":false},{"date":"2020-12-31","value":-21,"profit":false},{"date":"2021-12-31","value":-57,"profit":false},{"date":"2022-12-31","value":-76,"profit":false},{"date":"2023-12-31","value":-65,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CTSO | |
---|---|
Cash Ratio | 674.40 |
Current Ratio | 1968.80 |
Quick Ratio | 1583.55 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CTSO | |
---|---|
ROA (LTM) | -27.93% |
ROE (LTM) | -118.50% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CTSO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.73 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.27 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CTSO | |
---|---|
Trailing PE | NM |
Forward PE | 7.73 |
P/S (TTM) | 1.25 |
P/B | 3.42 |
Price/FCF | NM |
EV/R | 1.94 |
EV/Ebitda | NM |
PEG | NM |
Cytosorbents Crp (CTSO) share price today is $0.858
Yes, Indians can buy shares of Cytosorbents Crp (CTSO) on Vested. To buy Cytosorbents Crp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CTSO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cytosorbents Crp (CTSO) via the Vested app. You can start investing in Cytosorbents Crp (CTSO) with a minimum investment of $1.
You can invest in shares of Cytosorbents Crp (CTSO) via Vested in three simple steps:
The 52-week high price of Cytosorbents Crp (CTSO) is $1.88. The 52-week low price of Cytosorbents Crp (CTSO) is $0.7.
The price-to-earnings (P/E) ratio of Cytosorbents Crp (CTSO) is
The price-to-book (P/B) ratio of Cytosorbents Crp (CTSO) is 3.42
The dividend yield of Cytosorbents Crp (CTSO) is 0.00%
The market capitalization of Cytosorbents Crp (CTSO) is $44.52M
The stock symbol (or ticker) of Cytosorbents Crp is CTSO